Helix BioPharma (HBP) Stock Price, News & Analysis

Company Overview

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today's hardest-to-treat cancers. The Company's pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today's front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix's next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery. The Company also advances two pre-IND candidates: (i) LEUMUNA¿, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and (ii) GEMCEDA¿, a first-in-class oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.

Key Stats

• Today's Range: C$1.77 to C$2.10
• 50-Day Range: C$1.51 to C$2.10
• 52-Week Range: C$0.84 to C$5.40
• Volume: 11,745 shs
• Average Volume: 2,637 shs
• Market Capitalization: C$155.81 million
• P/E Ratio: N/A
• Dividend Yield: 1.50%
• Price Target: N/A
• Consensus Rating: N/A

HBP Stock Analysis - Frequently Asked Questions

How have HBP shares performed this year?

Helix BioPharma's stock was trading at C$2.37 at the beginning of the year. Since then, HBP shares have decreased by 13.9% and is now trading at C$2.04.

How were Helix BioPharma's earnings last quarter?

Helix BioPharma Corp. (TSE:HBP) posted its earnings results on Thursday, October, 24th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter.

How do I buy shares of Helix BioPharma?

Shares of HBP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Helix BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Helix BioPharma investors own include Enterprise Products Partners (EPD), GrowGeneration (GRWG), Green Thumb Industries (GTBIF), Amplify Seymour Cannabis ETF (CNBS), Cenovus Energy (CVE), Enbridge (ENB) and Micron Technology (MU).

Company Calendar

• Last Earnings: 10/24/2024
• Today: 5/05/2026

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: TSE:HBP
• CIK: N/A
• Web: www.helixbiopharma.com
• Phone: +1-416-9253232
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C($0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$50.55 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -36.79%
• Return on Assets: -279.98%

Debt

• Debt-to-Equity Ratio: 2.34
• Current Ratio: 0.04
• Quick Ratio: 1.04

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.18 per share
• Price / Cash Flow: 11.32
• Book Value: C$0.20 per share
• Price / Book: 10.14

Miscellaneous

• Outstanding Shares: 76,378,000
• Free Float: N/A
• Market Cap: C$155.81 million
• Optionable: Not Optionable
• Beta: 0.40